{"id":8885,"date":"2026-10-26T14:47:35","date_gmt":"2026-10-26T11:47:35","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=8885"},"modified":"2026-10-26T14:47:38","modified_gmt":"2026-10-26T11:47:38","slug":"rycarma-surlorian-arm-210-duchenne-muscular-dystrophy","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/rycarma-surlorian-arm-210-duchenne-muscular-dystrophy\/","title":{"rendered":"RyCarma\u2019n\u0131n Surlorian (ARM 210) Aday\u0131, Duchenne Musk\u00fcler Distrofi Ara\u015ft\u0131rmalar\u0131na Do\u011fru \u0130lerliyor"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>RyCarma Therapeutics, Duchenne kas distrofisi (DMD) hastal\u0131\u011f\u0131nda da de\u011ferlendirilebilecek deneysel bir ila\u00e7 olan Surlorian'\u0131 (ARM 210) geli\u015ftirmektedir.<\/strong> \u015eirket, 26 Ekim 2026 tarihli duyurusunda, RYR1 ile ili\u015fkili miyopati i\u00e7in Faz 2 klinik denemesinde ilk hastan\u0131n tedavi g\u00f6rd\u00fc\u011f\u00fcn\u00fc do\u011frulad\u0131. RyCarma ayr\u0131ca, Duchenne kas distrofisi olan ki\u015filerde Surlorian'\u0131 de\u011ferlendirmek i\u00e7in a\u00e7\u0131k bir Ara\u015ft\u0131rma Ama\u00e7l\u0131 Yeni \u0130la\u00e7 (IND) ba\u015fvurusuna sahip oldu\u011funu da teyit etti.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u0130\u00e7indekiler<\/h2><nav><ul><li><a href=\"#what-is-surlorian-arm-210\">Surlorian (ARM 210) nedir?<\/a><\/li><li><a href=\"#surlorian-and-duchenne-muscular-dystrophy\">Surlorian ve Duchenne Kas Distrofisi<\/a><ul><li><a href=\"#ry-carmas-dmd-program-is-phase-2-ready\">RyCarma&#039;n\u0131n DMD Program\u0131 2. A\u015famaya Haz\u0131r<\/a><\/li><li><a href=\"#what-do-we-know-about-surlorians-clinical-results\">Surlorian&#039;nin Klinik Sonu\u00e7lar\u0131 Hakk\u0131nda Neler Biliyoruz?<\/a><\/li><\/ul><\/li><li><a href=\"#what-happens-next\">Bundan sonra ne olacak?<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 id=\"what-is-surlorian-arm-210\" class=\"wp-block-heading\">Surlorian (ARM 210) nedir?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Surlorian, kas h\u00fccreleri i\u00e7indeki kalsiyum sal\u0131n\u0131m\u0131n\u0131 kontrol etmeye yard\u0131mc\u0131 olan ryanodin resept\u00f6rlerini (RyR&#039;ler) hedefleyerek kas fonksiyonunu iyile\u015ftirmek i\u00e7in tasarlanm\u0131\u015f, deneysel, g\u00fcnde bir kez a\u011f\u0131zdan al\u0131nan k\u00fc\u00e7\u00fck molek\u00fcll\u00fc bir ila\u00e7t\u0131r.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu resept\u00f6rler kas kas\u0131lmas\u0131nda \u00f6nemli bir rol oynar. Surlorian, resept\u00f6rleri stabilize etmek ve anormal kalsiyum s\u0131z\u0131nt\u0131s\u0131n\u0131 azaltmak i\u00e7in tasarlanm\u0131\u015ft\u0131r; bu da kas h\u00fccrelerinin daha etkili \u00e7al\u0131\u015fmas\u0131na yard\u0131mc\u0131 olabilir. Gen terapilerinin aksine, Surlorian eksik distrofin proteinini do\u011frudan de\u011fi\u015ftirmeyi ama\u00e7lamaz.<\/p>\n\n\n\n<h2 id=\"surlorian-and-duchenne-muscular-dystrophy\" class=\"wp-block-heading\">Surlorian ve Duchenne Kas Distrofisi<\/h2>\n\n\n\n<h3 id=\"ry-carmas-dmd-program-is-phase-2-ready\" class=\"wp-block-heading\">RyCarma&#039;n\u0131n DMD Program\u0131 2. A\u015famaya Haz\u0131r<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>RyCarma&#039;n\u0131n resmi \u00fcr\u00fcn geli\u015ftirme plan\u0131na g\u00f6re, Duchenne kas distrofisi program\u0131 &quot;2. Faz&#039;a haz\u0131r&quot; olarak listelenmi\u015ftir.<\/strong> \u015eirketin son duyurusu ayr\u0131ca, DMD hastalar\u0131nda Surlorian&#039;yi de\u011ferlendirmek i\u00e7in a\u00e7\u0131k bir IND&#039;ye sahip oldu\u011funu da do\u011fruluyor. Daha fazla bilgi edinin: <a href=\"https:\/\/rycarma.com\/pipeline\/\" target=\"_blank\" rel=\"noreferrer noopener\">RyCarma Boru Hatt\u0131<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu \u00f6nemli bir geli\u015fme \u00e7\u00fcnk\u00fc RyCarma&#039;n\u0131n ilac\u0131 ilk RYR1 ile ilgili miyopati program\u0131n\u0131n \u00f6tesinde de geli\u015ftirmeye \u00e7al\u0131\u015ft\u0131\u011f\u0131n\u0131 g\u00f6steriyor. Ancak \u015firket hen\u00fcz bir DMD denemesi ba\u015flang\u0131\u00e7 tarihi, \u00e7al\u0131\u015fma tasar\u0131m\u0131 veya hasta uygunluk kriterleri a\u00e7\u0131klamad\u0131.<\/p>\n\n\n\n<h3 id=\"what-do-we-know-about-surlorians-clinical-results\" class=\"wp-block-heading\">Surlorian&#039;nin Klinik Sonu\u00e7lar\u0131 Hakk\u0131nda Neler Biliyoruz?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">RYR1 ile ili\u015fkili miyopatisi olan hastalar\u0131 i\u00e7eren daha \u00f6nceki bir Faz 1b \u00e7al\u0131\u015fmas\u0131nda, daha y\u00fcksek doz alan kat\u0131l\u0131mc\u0131larda proksimal kas g\u00fcc\u00fcnde iyile\u015fmeler g\u00f6r\u00fcld\u00fc ve daha az yorgunluk bildirildi. Daha \u00f6nceki \u00e7al\u0131\u015fmalar ayr\u0131ca olumlu bir g\u00fcvenlik ve tolere edilebilirlik profili de ortaya koymu\u015ftur.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bu bulgular \u00f6nc\u00fcl niteliktedir ve Duchenne kas distrofisi de\u011fil, RYR1 ile ili\u015fkili miyopati \u00fczerine yap\u0131lan \u00e7al\u0131\u015fmalardan elde edilmi\u015ftir.<\/strong> Surlorian'\u0131n DMD hastalar\u0131nda etkili veya g\u00fcvenli olaca\u011f\u0131n\u0131 kan\u0131tlamazlar.<\/p>\n\n\n\n<h2 id=\"what-happens-next\" class=\"wp-block-heading\">Bundan sonra ne olacak?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>RyCarma \u015fu anda RYR1 ile ili\u015fkili miyopatiye y\u00f6nelik Faz 2 \u00e7al\u0131\u015fmas\u0131n\u0131 ilerletiyor ve ilk sonu\u00e7lar\u0131n 2027&#039;nin ikinci yar\u0131s\u0131nda elde edilmesi bekleniyor.<\/strong> \u015eirketin Duchenne ile ilgili ataca\u011f\u0131 sonraki ad\u0131mlar, \u00f6zellikle klinik \u00e7al\u0131\u015fma protokol\u00fcn\u00fcn a\u00e7\u0131klanmas\u0131 ve hasta kayd\u0131 planlar\u0131, yak\u0131ndan takip edilmesi gereken \u00f6nemli geli\u015fmeler olacak.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>DMD toplulu\u011fu i\u00e7in Surlorian, izlenmesi gereken potansiyel bir ara\u015ft\u0131rma yakla\u015f\u0131m\u0131n\u0131 temsil etmektedir.<\/strong> Ancak, bu y\u00f6ntem hala deneysel bir tedavi olup, Duchenne kas distrofisi olan ki\u015filer i\u00e7in anlaml\u0131 faydalar sa\u011flay\u0131p sa\u011flayamayaca\u011f\u0131n\u0131 belirlemek i\u00e7in daha fazla klinik \u00e7al\u0131\u015fmaya ihtiya\u00e7 duyulacakt\u0131r.<\/p>","protected":false},"excerpt":{"rendered":"<p>RyCarma Therapeutics is developing Surlorian (ARM 210), an experimental drug that may also be evaluated in Duchenne muscular dystrophy (DMD). In its October 26, 2026, announcement, the company confirmed that the first patient had received treatment in a Phase 2 clinical trial for RYR1-related myopathy. RyCarma also confirmed that it has an open Investigational New [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":8888,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[934,935,936,933],"class_list":["post-8885","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-arm-210","tag-rycarma-therapeutics","tag-ryr1-myopathy","tag-surlorian"],"subtitle":"RyCarma Therapeutics, Duchenne kas distrofisi (DMD) i\u00e7in potansiyel ta\u015f\u0131yan deneysel bir ila\u00e7 olan Surlorian'\u0131 (ARM 210) geli\u015ftiriyor. DMD program\u0131 \"Faz 2'ye haz\u0131r\" olarak listeleniyor, peki bu hastalar ve aileler i\u00e7in ne anlama geliyor?","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8885","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=8885"}],"version-history":[{"count":3,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8885\/revisions"}],"predecessor-version":[{"id":8890,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8885\/revisions\/8890"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/8888"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=8885"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=8885"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=8885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}